SCHEMBL2657660

SCHEMBL2657660

[N]=Cc1cccc(C#N)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 3/20 0.53
GRIN2D O15399 2/20 0.51
GRIN3B O60391 2/20 0.51
GRIN1 Q05586 2/20 0.51
GRIN2A Q12879 2/20 0.51
GRIN2B Q13224 2/20 0.51
GRIN2C Q14957 2/20 0.51
GRIN3A Q8TCU5 2/20 0.51
P4HB P07237 8/20 0.46
ENPP2 Q13822 1/20 0.45
TSHR P16473 1/20 0.44
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
CLK4 Q9HAZ1 1/20 0.42
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2774364 0.84 FBP1 (0.65) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1687910 0.84 FBP1 (0.65) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3216977 0.80 FBP1 (0.51) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21574844 0.80 FBP1 (0.61) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2657662 0.80 FBP1 (0.51) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL67236 0.80 FBP1 (0.56) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL127878 0.80 GRIN2D (0.54) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9186668 0.80 FBP1 (0.61) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1547532 0.80 FBP1 (0.51) FBP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL195319 0.80 FBP1 (0.51) FBP1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US disclosed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US disclosed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP disclosed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB1, GABRA5, GABRB2 FBP1 1999/4885GRIN2D 69/4885GRIN3B 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.